After Ethics committee’s approval, clinical study will be registered on CTRI website. Children subjects of age between 06 to 11 years of both sex (inclusive) attending outpatient departments/consultation department of study site (s) will be screened for eligibility criteria. On screening visit, a written informed consent will be obtained from subject’s guardian/parents for their participation in the study. Subject’s demographic details will be taken. Subject will undergo clinical examination (general and systemic examination). Subject’s medical, surgical and treatment history will be taken. Subject’s current medication if any will be noted in the case record from (CRF). The subject will be considered for further evaluation as per the inclusion and exclusion criteria. Subject will be called next day morning on empty stomach for laboratory testing. Subject’s blood sample will be collected at the respective study centers for laboratory testing i.e. CBC, ESR, Hb%, Liver Function Tests, Renal Function test, HbA1c etc. Subject’s Urine Routine will be done. During screening visit and the entire study duration subjects will be advised to refrain from antioxidant agents, vitamins, health supplements, Nutraceuticals, Ayurvedic, Siddha, Unani, herbal /homeopathic medicines. A screening window of 14 days will be kept, in case if there is delay in availability of tests reports or in case few tests need to be repeated. Subject will be called for baseline visit assessment (day 0). On baseline visit, subject will be recruited in the study if he/she meets all the inclusion criteria. Subjects will then be randomized to one of the two study groups as per the computer generated randomization list. Subject’s parent/ guardian will be asked for occurrence of any adverse event during screening period. Subject will undergo clinical examination (general and systemic examination). Subject’s growth- change in weight (WHO z-score), anthropometric parameters and blood biochemical tests - Serum iron, Serum calcium will be assessed. The questionnaire for evaluation of development and behavior like- Motor activity, Cognition, memory, social skills , Attention and concentration, Over activity and impulsivity, Perception of space and directions, Concepts of time, Perception of visual forms and figures, Passivity/inactivity and Planning/organizing etc. and cardiopulmonary performance by VO2, will be assessed. At baseline visit and at every follow up visit (except last follow up visit), as per computer generated randomization list, subjects will be provided with containers each containing 350 gms (300 gms for 30 days + additional 50 gms for use if follow up is delayed maximum up to 5 days) of either ‘Kids Protein Supplement’ or Standard. Subject will be advised to consume given supplement in a dose of 10gms in the morning with 150 ml milk for 3 months. Subject will be advised to continue his concomitant medication other than antioxidant agents, vitamins, health supplements, Nutraceuticals, Ayurvedic, Siddha, Unani, herbal /homeopathic medicines etc. The record of concomitant medication will be kept in the CRF. Product compliance will be assessed by the investigator on every follow up visit. Subjects who continuously misses dosing for >3 consecutive days or total missed dose > 9 days during the study period will be treated as drop outs. Subjects will be allowed to come for follow up either 5 days prior or after the scheduled follow up visit, provided subject should continue the given treatment. Subjects will be called at respective study sites for follow up visits after every month up to 3 months after the baseline visit. On every follow up visit, Subject will undergo clinical examination. Subject’s growth- change in weight (WHO z-score), anthropometric parameters will be assessed. The questionnaire for evaluation of development and behavior like- Motor activity, Cognition, memory, social skills , Attention and concentration, Over activity and impulsivity, Perception of space and directions, Concepts of time, Perception of visual forms and figures, Passivity/inactivity and Planning/organizing will be assessed. Subject’s immunity profile no. of recurrent acute Upper Respiratory tract infection (URTI), no. of sick days per month will be assessed by the presence of any acute URTI, No. of days required to recover from episode of infection will be recorded. Subject’s change in appetite score, emotional Quotient Questionnaire will be assessed. On third follow up visit (i.e. Day 90) subject’s growth- change in weight (WHO z-score), anthropometric parameters and blood biochemical tests - Serum iron, Serum calcium will be assessed. The questionnaire for evaluation of development and behavior like- Motor activity, Cognition, memory, social skills , Attention and concentration, Over activity and impulsivity, Perception of space and directions, Concepts of time, Perception of visual forms and figures, Passivity/inactivity and Planning/organizing etc. and cardiopulmonary performance by VO2, will be assessed. Subject’s immunity profile no. of recurrent acute Upper Respiratory tract infection (URTI), no. of sick days per month will be assessed by the presence of any acute URTI, No. of days required to recover from episode of infection will be recorded. Subject’s change in appetite score, emotional Quotient Questionnaire will be assessed. Global assessment of overall improvement will be done by subject’s parent and investigator on last follow up visit. Palatability with dosage compliance will be assessed by the investigator and by subject of test product from baseline to end of the study. All the subjects will be closely monitored for any adverse event starting from baseline visit till the end of the study visit. After completion of 3 months of study treatment, all the subjects will be asked to stop trial medications and take advice of investigator for further treatment.